Dr. Apollina Goel-Assistant Professor
4204 Medical Education and Biomedical Research Facility (MERF)
The University of Iowa
Iowa City, IA 52242-1181
Tel : (319)384-4754
Our long-term goal is to develop novel, mechanism-based combination approaches (involving targeted radiation and cytotoxic drugs) for cancer therapy. Currently the lab is pursuing following lines of study:
- Incorporation of skeleton-targeted radiotherapy (STR) into therapeutic regimens for multiple myeloma. The overall goal of this project is to understand how best to target constitutive and radiation-induced NF-kB activation to inhibit downstream IL6 synthesis, which would selectively radiosensitize myeloma cells and prevent the development of myeloma-cell drug resistance in the bone marrow microenvironment. Strategies to circumvent oxidative stress-induced emergence of therapy-resistance in myeloma cells are being studied. Also, based on our knowledge of the major signaling pathways that drive the proliferation of myeloma cells, we are evaluating a panel of molecularly targeted drugs for their ability to selectively enhance the therapeutic index of radiation-based treatment in myeloma. The project has a direct extension to the use of STR-based combination approaches to other malignancies such as breast and prostate cancer.
- Incorporation of radiovirotherapy into therapeutic regimens for multiple myeloma. We have generated and characterized a novel oncolytic vesicular stomatitis virus (VSV) that expresses human thyroidal NIS, and demonstrated 1) feasibility of performing viral biodistribution studies by micro-SPECT/CT imaging, and 2) attained therapeutic responses by combining VSV-NIS with I-131 in mice bearing systemic myeloma. We are currently performing studies to assess the therapeutic benefit of combining radiovirotherapy with 153-Sm-EDTMP and radiosensitizing drugs in the treatment of advanced systemic myeloma and B-cell lymphoma.
- Incorporation of chemotherapy into therapeutic regimens for lymphoma. Radioimmunotherapy is an established and effective treatment modality in lymphoma. As part of UI-Mayo Lymphoma SPORE, we are studying the role of VLA-4 (α4β1 integrin) adhesion receptor in cell adhesion-mediated drug resistance (CAM-DR) and CAM radiation resistance (CAM-RR).
Brown CO, Salem K, Wager BA, Bera S, Singh N, Tiwari A, Choudhury A, Buettner GR, Goel A. IL-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by upregulating manganese superoxide dismutase. Biochemical Journal-Disease 2012. (Abstract)
Salem K and Goel A. Enhancing therapeutic radiation responses in multiple myeloma. 2012. Book Title: Radiation Therapy, ISBN 979-953-307-341-4. Published by InTech - Open Access Publisher. (Link)
Goel A, Spitz DR, Weiner GJ. Manipulation of cellular redox parameters for improving the therapeutic responses in B-cell lymphoma and multiple myeloma. Journal of Cellular Biochemistry 2012. (Abstract)
Tiwari A, Jung JJ, Inamdar SM, Brown CO, Goel A, Choudhury A. Endothelial cell migration on fibronectin is regulated by syntaxin 6-mediated a5b1 integrin recycling. Journal of Biological Chemistry 2011. (Abstract)
Manickam V, Tiwari A, Jung J, Bhattacharya R, Goel A, Mukhopadhyay D, Choudhury A. Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood 2010 (Abstract)
Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ, Goel A. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia 2010 (Abstract)
Mooney SM, Goel A, D’Assoro AB, Salisbury JL, Janknecht R. Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. Journal of Biological Chemistry 2010 (Abstract)
Goel A, Carlson SK, Classic KL, Greiner S, Power AT, Bell JC, Russell SJ. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(D51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007 (Abstract)
Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, and Russell SJ. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletal targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006 (Abstract)
Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, and Russell SJ. PS-341 induces selective radiosensitization of multiple myeloma cells. Experimental Hematology 2005 (Abstract)
Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. Journal of Biological Chemistry 2004 (Abstract)
Goel A, Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF and HER2/Neu. Molecular & Cellular Biology 2003 (Abstract)
Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Batra SK. Biodistribution and radioimmunolocalization of human colon carcinoma xenografts with technecium-99m-labeled multivalent CC49 single-chain Fvs. (Abstract) .
Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Pavlinkova G, Tempero M, Batra SK. Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain Fvs. Clinical Cancer Research 2001 (Abstract)
Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJM, Pavlinkova G, Batra SK. Pharmacokinetics and biodistribution of a genetically-engineered tetravalent single-chain Fv of the tumor-associated glycoprotein TAG-72. Cancer Research 2000 (Abstract)
Goel A, Colcher D, Koo J, Booth BJM, Pavlinkova G, Batra SK. Relative position of the hexa-histidine tag effects the binding properties of the CC49 single-chain Fv. Biochim. Biophys. Acta 2000 (Abstract)
Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJM, Baranowska-Kortylewicz J, Batra SK. Divalent form of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification and characterization. J. Biochemistry 2000 (Abstract)
Honors, Awards and Organizations
- 2008 Career Development Award, University of Iowa/Mayo Lymphoma SPORE (5 P50 CA97274).
- 2007 Senior Research Award from the Multiple Myeloma Research Foundation (MMRF).
- 2007 Travel award and oral presentation at International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, AZ.
- 2007 Research chair in the Phase I/II clinical trial “Chemotherapy using Velcade Combined with a Radioactive Agent, Quadramet, in Treating Patients with Relapsed or Refractory Multiple Myeloma” at Mayo Clinic, Rochester, MN.
- 2006 Development Research Project, University of Iowa/Mayo Lymphoma SPORE (5 P50 CA97274).
- 2002 Scientific commentary on the original article in Journal of Nuclear Medicine.
- 1994, 1992 Research Fellowships for graduate studies, Council of Scientific and Industrial Research, India.
- 1992 Graduate Aptitude Test in Engineering (GATE) Fellowship, Department of Education, Ministry of Human Resources Development, Government of India.
- 1991 Summer Research Fellowship, Centre for Cellular and Molecular Biology, India.
- 1990 Selected for Master of Science (Biotechnology) through an All India level Common Entrance Test conducted by Jawaharlal Nehru University, New Delhi, India.
- BS - Biology, Kanpur Univesity, India, 1992
- MS - Biotechnology, Poona University, India, 1994
- PhD - Biotechnology, Institute of Microbial Tech, Punjab University, India, 1998
- Postdoctoral fellow, University of Nebraska Medical Center, 1998-2000
- Senior Postdoctoral fellow, Mayo Clinic, 2000-2004
- Associate Consultant, Molecular Medicine Program, Mayo Clinic, 2004-2007
- Research Scientist, Department of Radiation Oncology, University of Iowa, IA, 2007-2008